{
    "clinical_study": {
        "@rank": "28538", 
        "arm_group": [
            {
                "arm_group_label": "alpha-cyclodextrin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "A placebo comparator composed of the same acid resistant HPMC capsules filled with 300mg of alpha cyclodextrin"
            }, 
            {
                "arm_group_label": "Sulforadex", 
                "arm_group_type": "Experimental", 
                "description": "100mg or 300mg size 00 acid resistant HPMC capsules"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the safety and tolerability of multiple doses of Sulforadex\u00ae in healthy male\n      volunteers over 7 days with qd or bid dosing"
        }, 
        "brief_title": "Sulforadex in Healthy Human Males MAD", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This study will be conducted in a randomised, double-blind, placebo-controlled design with\n      multiple ascending doses of Sulforadex\u00ae administered qd [once daily] or bid [twice daily])\n      to healthy male subjects between 18 to 45 years of age."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject is a healthy male of any race aged 18 to 45 years, inclusive, at screening.\n\n          2. Subject has a BMI of 18 - 25 kg/m2 inclusive at screening.\n\n          3. Subjects must agree to use acceptable methods of contraception,\n\n          4. Subjects should not donate sperm from the time of the first administration of\n             treatment or study medication until 3 months following administration of the last\n             treatment or dose of study medication.\n\n          5. Subjects must be capable of understanding and complying with the requirements of the\n             protocol and must have signed the ICF prior to undergoing any study-related\n             procedures.\n\n        Exclusion Criteria:\n\n          1. All subjects must refrain from eating brassica vegetables or using brassica\n             containing supplements for at least 7 days prior to the drug administration. Brassica\n             vegetables include cabbage, cauliflower, horseradish, landcress, Ethiopian mustard,\n             kale, collard greens, Chinese broccoli, brussels sprouts, Kohlrabi broccoli, broccoli\n             flower, broccoli romanesco, wild broccoli, bok choy, Komatsuna, mizuna, rapini,\n             flowering cabbage, Chinese cabbage, Napa cabbage, turnip root, rutabaga, canola/rape\n             seed, Siberian kale, wrapped heart mustard cabbage, mustard seed (brown, black,\n             white), tatsoi, rocket (arugula), garden cress, water cress, radish, daikon and\n             wasabi.\n\n          2. Subject has a clinically significant disease or any condition or disease that might\n             affect drug absorption, distribution or excretion.\n\n          3. Any clinically significant abnormal laboratory, vital signs or other safety findings\n             as determined by medical history, physical examination or other evaluations conducted\n             at screening or on admission.\n\n          4. ECG abnormalities in the standard 12-lead ECG (at screening) which in the opinion of\n             the Investigator is clinically relevant or will interfere with the ECG analysis.\n\n          5. History or current evidence of any clinically relevant cardiovascular, pulmonary,\n             hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic,\n             neurological, psychiatric, or other disease.\n\n          6. Positive results in any of the serology tests for Hepatitis B Surface Antigen\n             (HbsAg), anti Hepatitis core antibody (anti HBc Ig G [and anti HBc IgM if IgG is\n             positive], Hepatitis C virus antibodies (anti HCV), and human immunodeficiency virus\n             HIV 1 and 2 antibodies (anti HIV 1/2).\n\n          7. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines,\n             cocaine, cannabinoids, opiates, barbiturates, tricyclic antidepressants and\n             methadone) or from the alcohol breath test at screening and on admission (Day -1).\n\n          8. History or clinical evidence of alcohol or drug abuse.\n\n          9. Mentally handicapped."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055716", 
            "org_study_id": "EVG002N"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sulforadex", 
                "intervention_name": "Sulforadex", 
                "intervention_type": "Drug", 
                "other_name": "Stabilised sulforaphane"
            }, 
            {
                "arm_group_label": "alpha-cyclodextrin", 
                "intervention_name": "alpha-cyclodextrin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sulforafan"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "contact": {
                "email": "j.taubel@richmondpharmacology.com", 
                "last_name": "Jorg Taubel", 
                "phone": "+44(0)20 8664 5200"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "SW17 0RE"
                }, 
                "name": "Richmond Pharmacology Limited"
            }, 
            "investigator": {
                "last_name": "Jorg Taubel, MD FFPM", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Sulforadex\u00ae in Healthy Male Subjects Following Daily Dosing for 7 Days", 
        "overall_contact": {
            "email": "j.taubel@richmondpharmacology.com", 
            "last_name": "J\u00f6rg J\u00f6rg T\u00e4ubel, MD FFPM", 
            "phone": "+44(0)20 8664 5200"
        }, 
        "overall_contact_backup": {
            "last_name": "Keith Keith Berelowitz", 
            "phone": "+44(0)20 8664 5200"
        }, 
        "overall_official": {
            "affiliation": "Richmond Pharmacology Limited", 
            "last_name": "J\u00f6rg T\u00e4ubel, MD FFPM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Safety assessments will include standard laboratory safety tests (haematology, biochemistry, coagulation and urinalysis), vital signs, physical examinations, 12-lead ECG, telemetry and AE monitoring.", 
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055716"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Plasma sulforaphane concentrations will be measured by LCMS/MS assay.\n\u2022 Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t).", 
            "measure": "Area under the plasma concentration versus time curve (AUC) of sulforaphane", 
            "safety_issue": "No", 
            "time_frame": "time 0, 30 min 1 2 4 8 12 & 24 hrs post dose on days 1,2 & 7"
        }, 
        "source": "Evgen Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Evgen Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}